GLP1R and diabetes mellitus: Notably, multiple large CVOTs have shown that GLP-1 RAs lower the risk of major adverse cardiovascular events (MACE), especially non-fatal stroke and cardiovascular death, in patients with diabetes and elevated baseline cardiovascular risks [14].